Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary

Blank Section (Placeholder)

Don’t Poor Lives Matter?

by Henry I. Millervia Hoover Digest
Friday, January 27, 2017

Regulation that chokes off investment hits everyone in the pocketbook, but the poor also pay with their health. 

an image

To Modulate Drug Prices, We Need Less Regulation And More Competition

by Henry I. Miller, John Cohrssenvia National Review
Wednesday, January 25, 2017

Allowing drugs in the U.S. that have been approved abroad would greatly help patients, providers, and producers. 

Analysis and Commentary

The Purpose Of The Military Is To Defend The Homeland, Not Promote Wind Turbines

by Henry I. Millervia Forbes
Wednesday, January 25, 2017

“The business of America is business,” President Calvin Coolidge famously said. He might have added that the business of the nation’s military is to defend America—not the promotion of radical environmentalism. (Duh.) 

Analysis and Commentary

Fixing FDA Is Literally A Matter Of Life And Death

by Henry I. Miller, Jeff Stiervia The Hill
Wednesday, January 18, 2017

In a December 60 Minutes interview, House Speaker Paul Ryan spoke of the need for regulatory reform.

Analysis and Commentary

The Anti-Science Seed Treaty

by Henry I. Miller, Drew L. Kershenvia Project Syndicate
Tuesday, January 17, 2017

In September, the United States ratified the International Treaty on Plant Genetic Resources for Food and Agriculture, known as the International Seed Treaty. Like so many international agreements crafted under the auspices of the United Nations, it is severely flawed. Indeed, the Seed Treaty is a politically correct, anti-technology fiasco.

Analysis and Commentary

This Could Be The Moment For Rolling Back Regulators' 'Soft Despotism'

by Henry I. Millervia Forbes
Wednesday, January 11, 2017

Bill McGurn in a recent Wall Street Journal column condemned the “soft despotism” in our government that has been created by “the unelected and increasingly assertive class that populates our federal bureaucracies and substitutes rule by regulation for the rule of law.” 

Analysis and Commentary

FDA’s Committees Provide Political Cover

by Henry I. Millervia The Wall Street Journal
Tuesday, January 10, 2017

[Subscription Required] Today, advisory committee meetings are held often when the FDA wants to political cover for a decision that has already been made.

Analysis and Commentary

As Americans’ Life Expectancy Drops, We Need More Medical Innovation

by Henry I. Millervia National Review
Monday, January 9, 2017

Americans’ life expectancy has dropped, but technology and laws to encourage innovation can help.

Analysis and Commentary

The FDA’s Dr. Nos

by John Cohrssen, Henry I. Millervia Cato Institute
Thursday, January 5, 2017

The agency’s fear of Type II errors inhibits drug development and harms patients.

Analysis and Commentary

Rachel Carson's 'Heedless And Destructive Acts'

by Henry I. Millervia Forbes
Wednesday, January 4, 2017

Environmental activists gathered last month in Washington DC to celebrate the legacy of the late author Rachel Carson, who gained fame for her book, “Silent Spring.” They’d have done better to pick up trash at a local park. As the Competitive Enterprise Institute’s Dr. Angela Logomasini wrote:...